ADAR1 Capital Management, LLC sold $96M of KROS
owner at Keros Therapeutics, Inc.. 5,389,264 shares at an average of $17.75, traded Oct 15, 2025, filed Oct 15, 2025.
Score components
- +12Role10% owner
- +25Trade size$95.7M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-25-004411, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | SOpen-market sale Common Stockindirect: By ADAR1 Partners, LP | -4,391,237 | $17.75 | $78M | 0 | Oct 15, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stockindirect: By ADAR1 SPVI, LP | -254,669 | $17.75 | $4.5M | 0 | Oct 15, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stockindirect: By Spearhead Insurance Solutions IDF, LLC | -743,358 | $17.75 | $13M | 0 | Oct 15, 2025 |
Related signals
Other insiders at Keros Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $10k 1,000 shares | +6% | |
| 26Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $11k 1,000 shares | +12% | |
| 16Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $12k 1,000 shares | +13% | |
| 14Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $22k 2,000 shares | +37% | |
| 44Moderate | Keros Therapeutics, Inc. | Esther Cho SVP, General Counsel | $78k 4,745 shares | -11% | |
| 50Moderate | Keros Therapeutics, Inc. | Keith Regnante CHIEF FINANCIAL OFFICER | $77k 4,739 shares | -11% | |
| 50Moderate | Keros Therapeutics, Inc. | Jasbir Seehra CHIEF EXECUTIVE OFFICER | $113k 7,015 shares | -2% | |
| 43Moderate | Keros Therapeutics, Inc. | Lorena Raquel Lerner Chief Science Officer | $63k 3,873 shares | -11% | |
| 78Notable | Keros Therapeutics, Inc. | Tomer Kariv director, owner | $85M 4,787,331 shares | -210% | |
| 38Weak | KROSbuy Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | $9.5M 934,258 shares | +27% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.